- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-2-mer
- Ligands
- 10 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)(Non-covalent)
- 4 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA.2: 4 residues within 4Å:- Chain A: N.717, F.718, L.922, Q.1071
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.13: 3 residues within 4Å:- Chain C: N.717, F.718, Q.926
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.15: 1 residues within 4Å:- Chain C: N.801
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.16: 3 residues within 4Å:- Chain C: N.331, Q.580, L.582
No protein-ligand interaction detected (PLIP)- 1 x NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 1 x NAG- NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(5-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 28 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.17: 2 residues within 4Å:- Chain A: N.280, N.282
Ligand excluded by PLIPNAG.18: 1 residues within 4Å:- Chain A: N.657
Ligand excluded by PLIPNAG.19: 1 residues within 4Å:- Chain A: N.616
Ligand excluded by PLIPNAG.20: 2 residues within 4Å:- Chain A: N.709, G.1131
Ligand excluded by PLIPNAG.21: 4 residues within 4Å:- Chain A: Y.28, F.59, N.61, P.631
Ligand excluded by PLIPNAG.22: 1 residues within 4Å:- Chain A: N.234
Ligand excluded by PLIPNAG.23: 3 residues within 4Å:- Chain A: N.603, T.604, P.942
Ligand excluded by PLIPNAG.24: 1 residues within 4Å:- Chain A: N.165
Ligand excluded by PLIPNAG.25: 2 residues within 4Å:- Chain A: F.342, N.343
Ligand excluded by PLIPNAG.26: 3 residues within 4Å:- Chain A: N.1074, F.1075, T.1076
Ligand excluded by PLIPNAG.27: 3 residues within 4Å:- Chain A: K.558
- Chain B: N.280, N.282
Ligand excluded by PLIPNAG.28: 1 residues within 4Å:- Chain B: N.657
Ligand excluded by PLIPNAG.29: 2 residues within 4Å:- Chain B: N.616, T.618
Ligand excluded by PLIPNAG.30: 2 residues within 4Å:- Chain B: N.709, G.1131
Ligand excluded by PLIPNAG.31: 2 residues within 4Å:- Chain B: F.59, N.61
Ligand excluded by PLIPNAG.32: 2 residues within 4Å:- Chain B: G.232, N.234
Ligand excluded by PLIPNAG.33: 3 residues within 4Å:- Chain B: K.310, N.603, T.604
Ligand excluded by PLIPNAG.34: 1 residues within 4Å:- Chain B: N.165
Ligand excluded by PLIPNAG.35: 3 residues within 4Å:- Chain B: N.1074, T.1076, N.1098
Ligand excluded by PLIPNAG.36: 1 residues within 4Å:- Chain C: N.657
Ligand excluded by PLIPNAG.37: 2 residues within 4Å:- Chain C: N.616, T.618
Ligand excluded by PLIPNAG.38: 2 residues within 4Å:- Chain C: N.709, G.1131
Ligand excluded by PLIPNAG.39: 2 residues within 4Å:- Chain C: F.59, N.61
Ligand excluded by PLIPNAG.40: 3 residues within 4Å:- Chain C: G.232, I.233, N.234
Ligand excluded by PLIPNAG.41: 2 residues within 4Å:- Chain C: N.603, T.604
Ligand excluded by PLIPNAG.42: 1 residues within 4Å:- Chain C: N.165
Ligand excluded by PLIPNAG.43: 2 residues within 4Å:- Chain C: F.342, N.343
Ligand excluded by PLIPNAG.44: 4 residues within 4Å:- Chain C: N.1074, F.1075, T.1076, S.1097
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Walter, J.D. et al., Biparatopic sybodies neutralize SARS-CoV-2 variants of concern and mitigate drug resistance. Embo Rep. (2022)
- Release Date
- 2021-08-04
- Peptides
- Spike glycoprotein: ABC
sybody#68: DE - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
BB
CC
ED
AE
D
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-2-mer
- Ligands
- 10 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)(Non-covalent)
- 4 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 1 x NAG- NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(5-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 28 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Walter, J.D. et al., Biparatopic sybodies neutralize SARS-CoV-2 variants of concern and mitigate drug resistance. Embo Rep. (2022)
- Release Date
- 2021-08-04
- Peptides
- Spike glycoprotein: ABC
sybody#68: DE - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
BB
CC
ED
AE
D